Tag Archives: MRK

Top 5 Value Stocks To Invest In Right Now

Elevate Credit has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company has decided to price its 12.4 million shares at $6.50 per share, with an overallotment option for an additional 1.86 million shares. At this price the entire offering is valued up to $92.69 million. The company intends to list its shares on the New York Stock Exchange under the symbol ELVT.

The underwriters for the offering are UBS Investment Bank, Credit Suisse, Jefferies, Stifel and William Blair.

The company had decided to postpone its offering back in January, but now it is back on the table.

The company offers technology-driven online credit solutions to non-prime consumers. This is for consumers with credit scores of less than 700 and who are not well-served by either banks or legacy non-prime lenders. These non-prime consumers approximately 170 million people in the United States and United Kingdom now represent a larger market than prime consumers but are difficult to underwrite and serve with traditional approaches.

Top 5 Value Stocks To Invest In Right Now: Lucas Energy, Inc.(LEI)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    The Interior Department is in charge of managing regulations around oil and gas drilling around the nation. Currently, the favorite appears to be Forrest Lucas, the 74-year-old founder of Lucas Energy Inc. (NYSEMKT: LEI). A career energy executive, Lucas recently told Investors Business Daily that he would be interested in the job because “it’s a very important position and you need to have someone in there who knows what they’re doing.” However, Lucas has never actually met Trump in person.

Top 5 Value Stocks To Invest In Right Now: Female Health Company (The)(FHCO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Female Health Co (NASDAQ: FHCO) were down 15 percent to $1.46 as the company reported that it has entered into a merger agreement with Aspen Park Pharma.

Top 5 Value Stocks To Invest In Right Now: Nuveen Municipal Value Fund Inc.(NUV)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top 5 Value Stocks To Invest In Right Now: Canterbury Park Holding Corporation(CPHC)

Advisors’ Opinion:

  • [By Sally Jones]

    Canterbury Park Holding Corporation (CPHC) Market Cap $46.35 Million

    Canterbury Park Holding Corporation is up 2% over 12 months. The company has a market cap of $46.35 million; its trades around $11.16 with a P/E ratio of 59.30 and a P/B of 1.70.

Top 5 Value Stocks To Invest In Right Now: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Keith Speights]

    With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.

  • [By Shanthi Rexaline]

    See also: 3 Reasons Alcoa Is No Longer The Curtain-Raising Event Of Earnings Season

    5. DuPont
    Company: E I Du Pont De Nemours And Co (NYSE: DD). Date of Reporting: Tuesday, before the market open. EPS Estimate vs. Year-ago EPS: $1.29 versus $1.24. Revenue Estimate: $7.29 billion versus $7.06 billion. Stock Gain/Loss (year to date): 14.97 percent.
    6. AT&T
    Company: AT&T Inc (NYSE: T). Date of Reporting: Tuesday, after the market close. EPS Estimate vs. Year-ago EPS: $0.74 versus $0.72. Revenue Estimate: $39.82 billion versus $40.52 billion. Stock Gain/Loss (year to date): (-14.6 percent).
    7. Coca-Cola
    Company: The Coca-Cola Co (NYSE: KO). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $0.58 versus $0.60. Revenue Estimate: $9.65 billion versus $11.52 billion. Stock Gain/Loss (year to date): 8.32 percent.
    8. Boeing
    Company: Boeing Co (NYSE: BA). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $2.31 versus $2.47. Revenue Estimate: $23.07 billion versus $24.75 billion. Stock Gain/Loss (year to date): 36.03 percent.
    9. Procter & Gamble
    Company: Procter & Gamble Co (NYSE: PG). Date of Reporting: Thursday, before the market open. EPS Estimate vs. Year-ago EPS: $0.78 versus $0.79. Revenue Estimate: $16.02 billion versus $16.1 billion. Stock Gain/Loss (year to date): 4.98 percent.
    10. Verizon
    Company

  • [By The Ticker Tape]

    LLY recently suffered a setback when approval for the company’s new arthritis drug, co-developed with Incyte Corporation (NASDAQ: INCY), faced delays from the FDA. LLY and INCY disagreed with the FDA’s findings in a company press release and are confident the drug will still be approved in the future. Despite the company’s confidence in the drug, LLY stock dropped about 5% in trading the day the news came out. Even with that drop, it’s still up a little over 11% on the year, outperforming the S&P 500 (SPX) and some of its pharma peers: Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ).

  • [By Matthew Briar]

    Kudos to Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) for taking a leap forward in the war against diabetes. The two competitors-turned-partners for one joint venture recently announced the FDA and the European equivalent has accepted an application for permission to sell ertugliflozin and a couple of its derivatives. All the drugs/combos in question are part of the SGLT2 family, which essentially induce the kidneys to filter sugar out of the bloodstream for diabetics whose pancreas isn’t processing that sugar properly.

    It’s an interesting approach, though not one without a potential downside. By forcing the kidneys to do something they weren’t meant to do, eventually, could pose new problems.

    Cell MedX Corp (OTCMKTS:CMXC) is taking an entirely different approach to the treatment of diabetes. Rather than work around a failing pancreas as Merck and Pfizer have, Cell MedX is aiming to fix what’s broken for diabetics. That is, the company aims to restore a body’s cells that properly process sugar by turning them back “on” again using mild electrical currents.

    As much as biologists and the healthcare industry know about the human body, new discoveries are being made all the time regarding our makeup. One of the more recent medical revelations was figuring out animals are not just a collection of chemicals and organic matter, but also electrical impulses. Yes, the human body creates electricity, but more than that, a body can benefit from mild electrical currents, as an electrical charge can put a damaged cell back into its natural, healthy state.

    It may seem like a crazy idea at first, but know the FDA has already given the science of electromedicine the nod of approval as a treatment for chronic pain (called the Cefaly, if you’re curious), and some major companies are wading deeper into electromedicine waters.

    As Scientific American’s Daisy Yuhas noted back in 2013:

  • [By Nelson Hem]

    In Reshma Kapadia's "Hersh Cohen Shares His Top Dividend Picks," see what ClearBridge Investments fund manager Harry "Hersh" Cohen sees in top dividend payers such as Merck & Co., Inc. (NYSE: MRK) and Schlumberger Limited. (NYSE: SLB). He also shares his thoughts on whether the market is putting in a top, what contributes to market complacency and more.

Top 10 Blue Chip Stocks To Buy Right Now

I will get right to it. After describing the reasons behind its meteoric rise and the discussing why this name was one of my top blue chip top picks for 2017, it comes down to performance. Just this morning Bank of America (NYSE:BAC), as well as other large banks, are out with key earnings reports. This matters for the 2017 call and it matters for the share price which has skyrocketed in the last few months. It’s about the performance. Performance not just on the top and bottom lines but also in several key metrics that I follow closely for all major banks. The bank has come a long way from it facing extinction, and it took we the people to keep it alive. Today Bank of America is one of the largest banks in the United States by assets and yes, it has recovered from the Great Recession. Is it firing on all cylinders like it was pre-recession? No, unfortunately it is not, but it is getting there. Can you stick with the name? We need to examine the company’s most recent earnings and key metrics to make that determination.

Top 10 Blue Chip Stocks To Buy Right Now: MFRI Inc.(MFRI)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggestedsmall cap piping systems stock MFRI, Inc (NASDAQ: MFRI) as a short-term long/bullish trade:

Top 10 Blue Chip Stocks To Buy Right Now: Wal-Mart Stores, Inc.(WMT)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    China has a growing middle class and affluent consumers who have strong aspirational demand for western luxury goods. Last year Chinese tourists spent $183 billionon shopping sprees abroad, a good deal of them for buying luxury goods. According to a report on Mintel.com, 58% of the Chinese consumers have boughtforeign goods from local online eCommerce sites. Alibaba has used this trend to build its TmallGlobal. In the just concluded Singles’ day sale, thousands of foreign brands including Walmart (NYSE:WMT) and Apple (NSDQ:AAPL) had participated. A retaliatory tax increase by China on foreign goods will impact the sale of foreign goods. The sale of foreign brands is expected to produce around $2 billion in incremental revenue by next year. A trade war between the US and China willsignificantly impact this revenue source.

  • [By Peter Graham]

    A long term performance chart shows shares of large cap dollar stores Dollar Tree and Dollar General Corp (NYSE: DG) both outperforming Wal-Mart Stores, Inc (NYSE: WMT) and largely given investors roughly the same return:

  • [By Rich Smith]

    Third and finally, Plug’s move closer to Amazon is resulting in customer attrition among the company’s other customers, including Wal-Mart (NYSE:WMT), which may not want to patronize Plug products in the future, knowing that the company is so closely tied to (and may soon be part owned by) Amazon.

Top 10 Blue Chip Stocks To Buy Right Now: Staples, Inc.(SPLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Staples, Inc. (NASDAQ: SPLS) got a boost, shooting up 7 percent to $9.25 on chatter that the company is targeted for an acquisition. Sycamore Partners, a private equity giant, is reportedly in advanced talks to acquire the office supply retailer, Reuters reported. The deal could value Staples at more than $6 billion, a premium to Staples' valuation of $5.60 billion as of Wednesday's market close.

  • [By Casey Wilson]

    The company was set to merge with its last remaining rival, Staples Inc. (Nasdaq: SPLS), this year, but was denied by a federal judge on May 10 because of antitrust concerns.

  • [By Jeremy Bowman]

    Staples Inc(NASDAQ:SPLS) stock has been on a tear over the last few days amid rumors of a potential buyout.According toThe Wall Street Journal, the company is in talks with private-equity firms to sell itself after regulators blew up its planned merger withOffice Depot(NASDAQ:ODP)last year.

  • [By Ben Levisohn]

    Staples (SPLS) soared to the top of the S&P 500 today on reports that the office-supplies retailer was considering selling itself.

    Agence France-Presse/Getty Images

    Staples gained 9.8% to $9.51 today, while the S&P 500 ticked up 0.1% to 2,360.16.

    CFRA’s Efraim Levy doesn’t see a “natural buyer” for Staples but remain Buy rated anyway:

    Shares are higher on an unconfirmed WSJ report that SPLS is looking at the possible sale of the company. Our fundamentally valued 12-month target of $11, applies a below historical average P/E of 12.1X our FY 18 EPS estimate, given office industry challenges. Our target has 11% upside, plus a 5.5% yield. We don’t see a natural buyer for a large physical store office supply presence, although an activist/private-equity buyer is a possibility. To make an acquisition worthwhile, a buyer would have to be more aggressive in cost cutting and use of cash flow than SPLS’s existing plan.

    Staples’ market capitalization rose to $6.2 billion today from $5.7 billion yesterday. It reported a net loss of $459 million on sales of $18.2 billion in fiscal 2017.

Top 10 Blue Chip Stocks To Buy Right Now: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By William Romov]

    BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) dropped about 2.9% Monday to post a new 52-week low of $53.63 after closing at $55.02 on Friday. The 52-week high is $66.80. Volume was around 12.7 million, more than 25% above the daily average of about 10 million. The company’s chief competitor in a combo therapy for lung cancer reported a successful phase 3 trial.

  • [By The Ticker Tape]

    LLY recently suffered a setback when approval for the company’s new arthritis drug, co-developed with Incyte Corporation (NASDAQ: INCY), faced delays from the FDA. LLY and INCY disagreed with the FDA’s findings in a company press release and are confident the drug will still be approved in the future. Despite the company’s confidence in the drug, LLY stock dropped about 5% in trading the day the news came out. Even with that drop, it’s still up a little over 11% on the year, outperforming the S&P 500 (SPX) and some of its pharma peers: Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ).

  • [By Matthew Briar]

    Kudos to Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) for taking a leap forward in the war against diabetes. The two competitors-turned-partners for one joint venture recently announced the FDA and the European equivalent has accepted an application for permission to sell ertugliflozin and a couple of its derivatives. All the drugs/combos in question are part of the SGLT2 family, which essentially induce the kidneys to filter sugar out of the bloodstream for diabetics whose pancreas isn’t processing that sugar properly.

    It’s an interesting approach, though not one without a potential downside. By forcing the kidneys to do something they weren’t meant to do, eventually, could pose new problems.

    Cell MedX Corp (OTCMKTS:CMXC) is taking an entirely different approach to the treatment of diabetes. Rather than work around a failing pancreas as Merck and Pfizer have, Cell MedX is aiming to fix what’s broken for diabetics. That is, the company aims to restore a body’s cells that properly process sugar by turning them back “on” again using mild electrical currents.

    As much as biologists and the healthcare industry know about the human body, new discoveries are being made all the time regarding our makeup. One of the more recent medical revelations was figuring out animals are not just a collection of chemicals and organic matter, but also electrical impulses. Yes, the human body creates electricity, but more than that, a body can benefit from mild electrical currents, as an electrical charge can put a damaged cell back into its natural, healthy state.

    It may seem like a crazy idea at first, but know the FDA has already given the science of electromedicine the nod of approval as a treatment for chronic pain (called the Cefaly, if you’re curious), and some major companies are wading deeper into electromedicine waters.

    As Scientific American’s Daisy Yuhas noted back in 2013:

Top 10 Blue Chip Stocks To Buy Right Now: Pain Therapeutics(PTIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Top 10 Blue Chip Stocks To Buy Right Now: ZAIS Group Holdings, Inc.(ZAIS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) got a boost, shooting up 48 percent to $3.35. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.

  • [By Lisa Levin]

    Shares of ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) got a boost, shooting up 42 percent to $3.22. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.

  • [By Lisa Levin] Related HTGM Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN … (GuruFocus)
    Related Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline Zais Group reports Q4 results (Seeking Alpha)
    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares climbed 204.1 percent to $11.95 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.
    ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) shares surged 52.6 percent to $3.45. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.
    Global Brokerage Inc (NASDAQ: GLBR) shares jumped 24.3 percent to $2.30.
    Regulus Therapeutics Inc (NASDAQ: RGLS) shares surged 20 percent to $1.50. Regulus Therapeutics’ Chairman bought 500,000 shares at $1.22 per share.
    Rocket Fuel Inc (NASDAQ: FUEL) shares gained 15.6 percent to $5.19.
    Akoustis Technologies Inc (NASDAQ: AKTS) rose 13.3 percent to $10.75 as the company agreed to acquire wafer manufacturing facility for $2.75 million in cash.
    TOP SHIPS Inc (NASDAQ: TOPS) shares gained 12.6 percent to $1.25.
    Inventure Foods Inc (NASDAQ: SNAK) jumped 10.4 percent to $4.46 after the company announced the strategic sale of Fresh Frozen Foods for $23.7 million in cash.
    CymaBay Therapeutics Inc (NASDAQ: CBAY) surged 8.7 percent to $4.14. Cymabay Therapeutics reported a Q4 loss of $0.30 per share.

Top 10 Blue Chip Stocks To Buy Right Now: Regal Entertainment Group(RGC)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Regal Entertainment Group (NYSE: RGC) was already rated as Underperform at Credit Suisse, but the firm said that the chain has weak trends and warned that its forecasts and multiples are just still too high. While raising some estimates, Sheikh lowered his target on Regal Entertainment to $17 from $19 in this call.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to
  • [By Peter Graham]

    In December, UK based Cineworld Group Plc also agreed tobuy larger U.S. peer Regal Entertainment Group (NYSE: RGC) for $3.6 billion in cash in adeal to create the world’s second largest movie theatre operator after AMC Entertainment Holdings. The combined entity is expected to be better able to compete AMC.

Top 10 Blue Chip Stocks To Buy Right Now: Applied Micro Circuits Corporation(AMCC)

Advisors’ Opinion:

  • [By Piyush Arora]

    AMD, along with other server-grade chip manufacturers such as Qualcomm (NSDQ:QCOM), Cavium (NSDQ:CAVM) and AMCC (NSDQ:AMCC), operates in the remaining minuscule 0.8% of the market. So, each of the aforementioned companies operate with a practically non-existent market share, compared to Intels shipments of course. This also means that these firms (AMD, Qualcomm etc.) have plenty of room to grow. This would be subject to good product releases of course, but at least this way, the law of large numbers isnt working against them.

Top 10 Blue Chip Stocks To Buy Right Now: Great Basin Scientific, Inc.(GBSN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Great Basin Scientific Inc. (NASDAQ: GBSN) dropped about 15% on Thursday to post a new 52-week low of $2.90 after closing at $3.42 on Wednesday. The stock’s 52-week high is $45,024.00. Volume was more than 3 times the daily average of around 150,000 shares. The medical diagnostics company had no specific news Thursday. Since mid-March the company has split the stock twice: the first was a 1-for-35 split and the second a 1-for-80 split.

  • [By Lisa Levin]

    Great Basin Scientific Inc (NASDAQ: GBSN) shares dropped 18 percent to $0.92 on Q1 results. Great Basin Scientific posted Q1 net income of $21,503,600, versus a year-ago net loss of $33,652,500.

Top 10 Blue Chip Stocks To Buy Right Now: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

stock market articles

Scotts Valley, CA, based Investment company Niemann Capital Management Inc buys First Trust NASDAQ-100- Technology Index Fund, SPDR Select Sector Fund – Utilities, PowerShares DWA Utilities Momentum Portfolio, VanEck Vectors Semiconductor, Guggenheim S&P 500 Equal Weight Technology, PowerShares Dynamic Semiconductors, SPDR S&P International Technology Sector, sells First Trust DJ Select MicroCap, First Trust NASDAQ ABA Community Bank Index Fund, iShares U.S. Broker-Dealers & Securities Exchanges, Guggenheim S&P Smallcap 600 Pure Value, SPDR S&P Metals & Mining during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Niemann Capital Management Inc. As of 2017-03-31, Niemann Capital Management Inc owns 7 stocks with a total value of $97 million. These are the details of the buys and sells.

New Purchases: QTEC, XLU, PUI, SMH, RYT, IPK, Added Positions: PSI, Sold Out: FDM, QABA, IAI, RZV, XME, FIW,

For the details of NIEMANN CAPITAL MANAGEMENT INC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=NIEMANN+CAPITAL+MANAGEMENT+INC

stock market articles: Gevo, Inc.(GEVO)

Advisors’ Opinion:

  • [By Paul Ausick]

    Gevo Inc. (NASDAQ: GEVO) dropped about 16 Wednesday to post a new 52-week low of $1.33 after closing Tuesday at $1.59. The 52-week high is $27.20. Volume of about 3.5 million was nearly 5 times the daily average of around 760,000 shares traded. On Tuesday the renewable chemicals and biofuels priced a secondary offering of 5.68 million shares at $1.90 per share, and also 570,000 units of three different warrants. Today’s drop was about half the size of Tuesday’s.

stock market articles: China Jo-Jo Drugstores, Inc.(CJJD)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap Chinese retail pharmacy stock China Jo-Jo Drugstores (NASDAQ: CJJD) as a bullish long trade:

stock market articles: TeleNav Inc.(TNAV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Telenav Inc (NASDAQ: TNAV) shares were also up, gaining 16 percent to $8.15 after the company reported the settlement of patent lawsuit. The company projects Q2 revenue of $51 million to $52 million and loss of $0.30 per share to $0.28 per share.

stock market articles: China Petroleum & Chemical Corporation(SNP)

Advisors’ Opinion:

  • [By Paul Ausick]

    The Permian Basin pipeline project includes an investment by China’s state-controlled China Petroleum & Chemical Corp. (NYSE: SNP), aka Sinopec. Other partners in the project include ArcLight Capital and Freepoint Commodities LLC. The deal also includes an expansion to oil storage facilities in the U.S. Virgin Islands, where recent hurricanes have caused so much damage. The project still requires approval from both countries governments.’

stock market articles: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Jefferies analyst Jeffrey Holford and aren’t feeling too upbeat about pharmaceutical stocks in 2017, noting that politics, as well as pharmacy benefit managers, could put downward pressure on pricing. Then there are the weakening fundamentals. As a result, they cut their rating Merck (MRK) to Underperform from Hold…

  • [By Chris Lange]

    Merck & Co., Inc. (NYSE: MRK) is expected to share its latest quarterly earnings on Friday. The consensus estimates are$0.87 in EPS on $9.74 billion in revenue. Shares were at $62.63 at Fridays close, in a 52-week range of $57.18 to $66.80. The consensus price target is $69.70.

  • [By WWW.THESTREET.COM]

    And second, if you go back too far in time you will find four outliers — Cisco (CSCO) , Intel (INTC) , Merck (MRK) and Pfizer (PFE) — that hit ridiculous levels that we cannot expect will be repeated any time soon. (Just to show you what absurdity looks like, Cisco touched $80 and Intel reached $74 in 2000, while Merck hit $89 and Pfizer got to $49 back in that same period.)

  • [By WWW.THESTREET.COM]

    A ransomware attack that struck government and businesses in the Ukraine and Europe Tuesday has affected Merck (MRK) and is spreading in the United States, according to a published report.

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) traded up 0.36% at $56.54. The stock’s 52-week range is $53.63 to $66.80. Volume was about 70% below the daily average of around 11.7 million shares. The company had no specific news.

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) traded down 0.68% at $64.26. The stock’s 52-week range is $51.33 to $66.80. Volume was about 40% below the daily average of nearly 10.8 million. There have been reports that lawsuits are coming related to the company’s Zostavax shingles vaccine.

The Worst 5 DJIA Stocks of 2017

Only five stocks among the 30 that make up the Dow Jones Industrial Average (DJIA) closed out 2017 with lower share prices than they started the year with. That’s really some accomplishment in a year that saw the Dow rise by more than 24%.

Some of the losers have struggled with growth for years while others were caught in an industry downturn that they couldn’t rise above. Two have new CEOs, one was hit by a massive ransomware attack, one was slow to react to intense competitive pressure and one simply has been too slow for too long.

Here’s a brief look at the five losers: General Electric Co. (NYSE: GE), International Business Machines Corp. (NYSE: IBM),Exxon Mobil Corp. (NYSE: XOM), Merck & Co. Inc. (NYSE: MRK) and Verizon Communications Inc. (NYSE: VZ).

General Electric

This was one of two Dow companies to change its CEO. Jeff Immelt, one of our worst CEOs of the year, was replaced in August by John Flannery, who watched the stock drift lower for two months before revealing his new strategy for the company. That didn’t help though, mainly because the strategy involves cutting costs, selling assets and generally getting smaller. Maybe the narrower focus will pay off, but investors aren’t so sure.Shares dropped nearly 45% in 2017 and closed the year at $17.45, just 20 cents above the 52-week low.

IBM

The first hit to the stock price came when Warren Buffett decided in May that he’d defended the tech giant long enough. Buffett cited increasing competition as the reason for Big Blue’s problems, but in reality the transformation of the company to a more cloud-oriented business under CEO Ginni Rometty (another of our worst CEOs of 2017) has been painfully slow.There is little evidence that 2018 will be much different from 2017, when the stock price fell by 7.6%.

Exxon

Exxon Mobil suffered through a poor first half of 2017 as crude oil prices fell into the $40 a barrel range after opening the year around $56. On Friday crude oil settled at just over $60 a barrel and Exxon, like many other oil producers, is expected to maintain a cautious approach to capital spending and do more to reward shareholders with buybacks and dividends. That should bolster the share price, but won’t do much to boost the company’s valuation, which is based primarily on its stockpile of proved barrels. Shares closed the year down 7.3%.

Merck

This pharmaceutical giant took a major hit from a ransomware attack in June that ended up costing the company more than $175 million in one-time charges and about $125 million in lost revenues in the third quarter. Worse, though is falling profits, down 48% for the trailing 12 months. The company has also withdrawn its application for European regulatory approval of its lung-cancer treatment and abandoned research on its hepatitis C drug. The stock dropped 4.4% in 2017.

24/7 Wall St.
Meet the Preliminary Dogs of the Dow for 2018 Verizon

A buzzsaw of competition hit Verizon early in the year, when a competitor introduced an unlimited data package that forced Verizon to counter, something it did not particularly want to do. The company also completed its purchase of Yahoo, part of an effort to diversify into something other than a provider of fat pipes. Then the FCC rolled back Obama-era net neutrality rules that potentially will allow Verizon and other internet backbone carriers to charge more for faster speeds. All this adds up to a view of Verizon as a value play for 2018 because the shares are just so cheap. The stock closed the year down just 0.8%, a sharp improvement from its 18% loss in early July.

Top 10 High Tech Stocks To Watch Right Now

U.S. equities finished near the unchanged line on Tuesday after recovering from deeper intraday losses.

Geopolitical tensions were in focus, with attention on North Korea and Syria. President Trump tweeted that Pyongyang was “looking for trouble” and that the United States would “solve the problem” if China didn’t help. Concerning Syria, the G7 countries failed to agree on new economic sanctions on Damascus following the recent chemical weapons attack.

The Dow Jones Industrial Average dropped a fraction, the S&P 500 lost 0.1%, the Nasdaq Composite gave back 0.2% and the Russell 2000 gained 0.7%. Treasury bonds rallied, the dollar was on the defensive, gold added 1.6% and oil gained 0.6% for its sixth consecutive rise. Energy benefited from reports that Saudi Arabia wants to extend last year’s production freeze agreement for another six months when OPEC meets again on May 25.

Yield-sensitive REITs led the way with a 0.4% gain while technology stocks were the laggards, down 0.4%. Trading was light, with NYSE volume at 88% of the 30-day average.

Top 10 High Tech Stocks To Watch Right Now: Inogen, Inc(INGN)

Advisors’ Opinion:

  • [By Michael A. Robinson]

    I put these rules in action for you in March 2015 when I recommendedInogen Inc.(Nasdaq: INGN)here in these pages.

    Inogen is pioneering the use of portable oxygen concentrators (POCs). And theGoleta, Calif.-based firm boasts breakthrough technology that has disrupted its entire sector.

Top 10 High Tech Stocks To Watch Right Now: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday’s regular session.

  • [By Arie Goren]

    Sales of Gileads blockbuster hepatitis C drugs Harvoni, Sovaldi and the new drug Epclusa, which was launched in the United States and Europe in June and July 2016, fell 16.6% compared to the previous quarter and 30.7% year-over-year to $3,325 million. The decline in Gileads HCV revenue has been mostly due to lower patient starts for Harvoni and lower revenues per patient, and the deep discount the company had to offer to maintain its high market share due to the competition from AbbVie’s (NYSE:ABBV)HCV drug Viekira, and Merck’s (NYSE:MRK)HCV drug Zepatier.

  • [By WWW.THESTREET.COM]

    And second, if you go back too far in time you will find four outliers — Cisco (CSCO) , Intel (INTC) , Merck (MRK) and Pfizer (PFE) — that hit ridiculous levels that we cannot expect will be repeated any time soon. (Just to show you what absurdity looks like, Cisco touched $80 and Intel reached $74 in 2000, while Merck hit $89 and Pfizer got to $49 back in that same period.)

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

  • [By WWW.MONEYSHOW.COM]

    Two of our top holdings, GlaxoSmithKline (GSK) and Merck (MRK) have seen substantial improvement in earnings as new drugs start to build market share. Glaxo and Merck offer dividend yields of 4.71% and 3.08%, respectively.

Top 10 High Tech Stocks To Watch Right Now: Natural Grocers by Vitamin Cottage, Inc.(NGVC)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) appearing to all be in downtrends that may or may not have leveled off:

  • [By Lisa Levin]

    Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC) was down, falling around 33 percent to $5.70 as the company posted downbeat quarterly results and lowered its FY17 earnings guidance.

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows along with mid cap peerSprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) largely drifting lower with two price spikes:

  • [By Peter Graham]

    A long term performance chart for Whole Foods Market shows shares still lower than they were five years ago whilepeers in the organic space like Sprouts Farmers Market Inc (NASDAQ: SFM) and Natural Grocers by Vitamin Cottage (NYSE: NGVC) have performed worst:

Top 10 High Tech Stocks To Watch Right Now: CPI Aerostructures, Inc.(CVU)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CPI Aerostructures, Inc. (NYSE: CVU) got a boost, shooting up 25 percent to $7.10 after the company posted upbeat Q1 results.

    Wayfair Inc (NYSE: W) shares were also up, gaining 25 percent to $63.71 after first-quarter earnings boasted a 2.7-percent sales beat and 46-percent year-over-year increase in active customers.

  • [By Lisa Levin]

    Shares of CPI Aerostructures, Inc. (NYSE: CVU) were down around 14 percent to $7.30 on downbeat quarterly results.

    IDT Corporation (NYSE: IDT) was down, falling around 15 percent to $15.88 following Q2 results. IDT reported fiscal second-quarter earnings of $875,000.

Top 10 High Tech Stocks To Watch Right Now: iShares Global Infrastructure (IGF)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Investors who are looking to invest in the companies that will likely be playing a central role in America’s infrastructure investment may want to consider the iShares S&P Global Infrastructure Index (NYSE: IGF).

  • [By WWW.THESTREET.COM]

    It also helps to find funds that can make any wait bearable and even profitable. Several ETFs stand out for their relatively low cost, modest risk and reasonable yields. They include the Guggenheim S&P High Income Infrastructure ETF (GHII) , iShares S&P Global Infrastructure Index Fund (IGF) and FlexShares STOXX Global Broad Infrastructure Index Fund (NFRA) .

Top 10 High Tech Stocks To Watch Right Now: Petroleo Brasileiro S.A.- Petrobras(PBR)

Advisors’ Opinion:

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results late Thursday. The consensus estimates call for a profit of $0.16 per share, as well as $23.81 billion in revenue. Shares ended the weekat $8.86. The consensus price target is $10.82, and the 52-week range is $7.61 to $12.56.

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Petroleo Brasileiro S.A.- Petrobras (NYSE: PBR): Free Stock Analysis Report
     
    Bill Barrett Corporation (NYSE: BBG): Free Stock Analysis Report
     
    Northern Oil and Gas, Inc. (AMEX:NOG): Free Stock Analysis Report
     
    Rice Midstream Partners LP (NYSE: RMP): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, decreased to 42.63 million shares from the previous 43.53 million. The stock traded at $9.06 a share, in a 52-week range of $5.19 to $12.56. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Craig Jones]

    Alan Knuckman of Bulls-Eye Option said on Bloomberg Markets that he would buy Petroleo Brasileiro SA Petrobras (ADR)(NYSE: PBR), because it could benefit from the strength in crude oil.

  • [By Money Morning News Team]

    Petroleo Brasileira SA Petrobras (NYSE ADR: PBR) is Brazil’s largest oil company and it’s our seventh best oil stock of 2016. Petrobras is an oil and natural gas exploration and production firm. It is also an operator of oil tankers, pipelines, and terminals in South America and globally.

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results Tuesday. The consensus estimates call for a net loss of $0.05 per share, as well as $18.05 million in revenue. Shares ended the weekat $8.91. The consensus price target is $11.22, and the 52-week range is $4.98 to $12.56.

Top 10 High Tech Stocks To Watch Right Now: Suzuki Motor Corporation (SZKMY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Elon has plans for a Gigafactory 3 somewhere in the US unlike the Gigafactory in Europe. If Tesla can get just two Gigafactories built, it will have the batteries at least to produce vehicles at about the same scale as Suzuki (OTCPK:SZKMY) (Suzuki made about 3mm autos in 2015). In fact, Tesla hopes to have the Gigafactory running flat out by 2020, supplying 3X the number of batteries it needs unless it can ramp production into 2020 further. These batteries will be used on the Tesla Power Walls and other power containment devices it has in its pipeline, but it sure seems that Tesla can ramp its auto production past the 500k units per year in 2019 and 2020. At the very least, it will likely have the batteries to do so.

Top 10 High Tech Stocks To Watch Right Now: Medley Capital Corporation(MCC)

Advisors’ Opinion:

  • [By Lee Jackson]

    Medley Capital Corp. (NYSE: MCC) is another company that had the man at the top buying shares. CEO Brook Taube added 188,336 shares of the business development company at prices that ranged from $7.13 to $7.48 per share. The total for the trade was posted at $1 million. The stock closed Friday at $7.26.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

Top 10 High Tech Stocks To Watch Right Now: Catabasis Pharmaceuticals, Inc.(CATB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) got a boost, shooting up 46 percent to $6.52. Catabasis Pharmaceuticals and Sarepta Therapeutics Inc (NASDAQ: SRPT) reported a joint research collaboration in Duchenne Muscular Dystrophy.

Top 10 High Tech Stocks To Watch Right Now: AquaVenture Holdings Limited (WAAS)

Advisors’ Opinion:

  • [By Jim Robertson]

    There were six IPOs scheduled for this week (five yesterday and one today) with small cap Aquaventure Holdings LLC (NYSE: WAAS) appearing set to end the week with shares above their IPO debut price. AquaVenture Holdings is a global leader in water purification solutions and a pioneer in providing Water-as-a-Service (WAAS), generating recurring revenue from the deployment of advanced water filtration, sanitization, purification and desalination technologies. Through its subsidiaries,the Companyserves over 40,000 customers and delivers seven billion gallons of clean water each year.

Caterpillar, UnitedHealth Lead DJIA Slide Thursday

December 14, 2017: Markets opened higher again Thursday but shares trickled lower throughout the day led by a drop of around 1% in the healthcare and materials sectors. Only consumer discretionary stocks posted a decent gain although tech stocks could also close the day with a tiny improvement. WTI crude oil for January delivery settled at $57.04 a barrel, up 0.8% for the day. February gold added 0.7% on the day to settle at $1,257.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.13% for the day, the S&P 500 traded down 0.27%, and the Nasdaq Composite traded down 0.18%.

Bitcoin futures for January traded at $16,860, down 1.14%, on the CBOE about an hour before settlement after opening at $17,0800 this morning. Only about 1,000 contracts had been traded.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was Caterpillar Inc. (NYSE: CAT) which traded down 1.33% at $146.60. The stock’s 52-week range is $90.34 to $149.05. Volume was about about equal to the daily average of around 3.5 million shares. The company reported a year-over-year November sales increase of 26% on Wednesday morning.

UnitedHealth Group Inc. (NYSE: UNH) traded down 1.23% at $221.58. The stock’s 52-week range is $156.09 to $231.77. Volume was about a third below the daily average of around 3 million shares. The company had no specific news.

Verizon Communications Inc. (NYSE: VZ) traded down 0.77% at $52.49. The stock’s 52-week range is $42.80 to $54.83. Volume was about 20% below the daily average of around 17 million. The company had no specific news.

Merck & Co. Inc. (NYSE: MRK) traded down 0.52% at $56.13. The stock’s 52-week range is $53.63 to $66.80. Volume was about 35% below the daily average of around 11.4 million shares. The company had no specific news.

Of the Dow stocks, 9 are on track to close higher Thursday and 21 are set to close lower.
24/7 Wall St.
4 Large Cap Biotech Leaders Are Huge Tax Reform Winners

stocks to invest in today

With Johnson & Johnson (JNJ) bouncing off record highs, BTIG has thrown in the towel on its buy rating. Analyst Dane Leone has downgraded the stock today to neutral from buy.J&J fell 0.63% to a recent $113.52.

Downgrading ahead of the Investor Day next week is a risk, but at this point we are not expecting any major strategic shifts. We remain interested in the long-term JNJ story, but also must acknowledge current levels of the stock price with regard to our thesis.

Why? Leone is less confident in the outlook for merger and acquisition activity in the medical device sector.” That had been a main driver of the firms prior “buy” rating. But with prices rising for Edward Lifesciences (EW) and other cardiovascular device companies, Leone is less optimistic that J&J will be able to execute on transformational deals.

Medical Device M&A has Been the Primary Miss to Our Thesis: The second pillar to our initial Buy rating was the expectation that JNJ management would execute transactions within the Medical Device industry, namely cardiovascular focused areas, which could help diversify its business away from the slow growing Orthopaedics market and also increase International exposure to more growth oriented geographies. There is still ample opportunity for M&A during the remainder of 2016, with ~$16.5bn of net cash on the balance sheet as of 3/31/2016, but recent price appreciation of cardiovascular growth companies such as Edwards Lifesciences (EW, Buy, $122 PT, Analyst: Sean Lavin), makes us less optimistic that 1) JNJ will be willing to execute on more transformational Medical Device M&A and 2) If executed, larger M&A would be meaningfully accretive. For example, our Accretion analysis of EW only suggests a ~4% EPS benefit within the first 12-months (2017), assuming a +20% transaction premium to the current share price along with ~$200m of first-year cost synergies baked into the transaction.

stocks to invest in today: Koppers Holdings Inc.(KOP)

Advisors’ Opinion:

  • [By Monica Gerson]

    Koppers Holdings Inc. (NYSE: KOP) is estimated to report its quarterly earnings at $0.09 per share on revenue of $364.50 million.

    DENTSPLY SIRONA Inc (NASDAQ: XRAY) is expected to report its quarterly earnings at $0.63 per share on revenue of $734.75 million.

stocks to invest in today: Carlsberg A/S (CABGY)

Advisors’ Opinion:

  • [By Mark Fritz]

    Price Target: $124.

    Heineken N.V. (ADR) (OTC: HINKY): Hold.
    Price Target: 82.30 euros.

    Carlsberg A/S (ADR) (OTC: CABGY): Hold.
    Price Target: 652 krones.

    Distillers

stocks to invest in today: New York Times Company (The)(NYT)

Advisors’ Opinion:

  • [By Ezra Schwarzbaum]

    Fox News (parent company, Twenty-First Century Fox Inc (NASDAQ: FOXA)) confirmed it dropped their long-time motto, “Fair and Honest,” on June 14, according to the New York Times (parent company, New York Times Co (NYSE: NYT)). It is the latest in a series of mainstream media rebranding moves since President Donald Trump took office.

  • [By Asit Sharma]

    The New York Times Company (NYSE:NYT) reported credible first-quarter earnings on May 5, as digital revenue offset continued declines in the company’s print media business. Excuse the pun, but after we review the “headline” numbers, we’ll delve into the quarter’s details, as well as the Times’ subscription and revenue outlook.

  • [By WWW.THESTREET.COM]

    As their digital advertising growth stalls, imperiled by that increasingly recognized ad duopoly of Alphabet’s Google (GOOGL) and Facebook (FB) , a wide range of publishers has turned to e-commerce, many within the past year. New York Times Co. (NYT) bought the Wirecutter review/commerce business in October, and it now plans to use it as a base for broader commerce plays. Both BuzzFeed and Vox also have announced forays, joined by Conde Nast and Hearst. Business Insider’s Insider Picks, meanwhile, is another business model proved out for the Axel Springer company and has become a significant profit contributor.

  • [By Shanthi Rexaline]

    Apple Inc. (NASDAQ: AAPL), which has a huge customer base in China, didn’t think it worthwhile to risk its business prospects in China. In January this year, the company removed the New York Times Co (NYSE: NYT) app from its app store in China.

  • [By WWW.THESTREET.COM]

    Riding on its recent momentum of passing the 3 million paid print and digital subscription mark, New York Times (NYT) has struck up a deal with Spotify in an attempt to lure even more readers to pay for news.

stocks to invest in today: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) traded up 0.93% at $66.07. The stock’s 52-week range is $65.40 to $66.80. Volume was around 10% below the daily average of about 8.8 million shares. The company had no specific news, but like J&J got a boost from the healthcare bill.

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) dropped about 2.9% Monday to post a new 52-week low of $53.63 after closing at $55.02 on Friday. The 52-week high is $66.80. Volume was around 12.7 million, more than 25% above the daily average of about 10 million. The company’s chief competitor in a combo therapy for lung cancer reported a successful phase 3 trial.

  • [By WWW.THESTREET.COM]

    A ransomware attack that struck government and businesses in the Ukraine and Europe Tuesday has affected Merck (MRK) and is spreading in the United States, according to a published report.

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) traded down 0.84% at $59.29. The stock’s 52-week range is $47.97 to $65.46. Volume was less than half the daily average of around 10.9 million shares. The drug maker had no specific news.

  • [By Paul Ausick]

    Merck & Co. Inc. (NYSE: MRK) dropped about 6.6% Monday to post a new 52-week low of $54.41 after closing at $58.24 on Friday. The stock’s 52-week high is $66.80. Volume of around 32 million was about four times the daily average. The drug maker said it had withdrawn its application for approval of a key lung cancer treatment.

stocks to invest in today: Euronet Worldwide Inc.(EEFT)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Green Dot Corporation back in positive territory after having drifted lower while potential payments peer mid capEuronet Worldwide, Inc (NASDAQ: EEFT) has continued to be an outperformer and small capBlackhawk Network Holdings Inc (NASDAQ: HAWK)is drifting higher:

  • [By Peter Graham]

    Blackhawk Network Holdingshas largelymovedsidewaysor slowly upward after its IPO spinoff from Safeway (NYSE: SWY) whilepotential peers like small capGreen Dot Corporation (NYSE: GDOT) and mid capEuronet Worldwide, Inc (NASDAQ: EEFT) have beenoutperformers:

  • [By Peter Graham]

    Small cap Blackhawk Network Holdingshas largely moved sidewaysafter its IPO spinoff from Safeway (NYSE: SWY) whilepotential peer of Green Dot Corporation (NYSE: GDOT) has underperformed and Euronet Worldwide, Inc (NASDAQ: EEFT) has outperformed:

  • [By Peter Graham]

    Small cap Blackhawk Network Holdingshas movedboth sidewaysor slowly upward after its IPO spinoff from Safeway (NYSE: SWY) whilepotential peer of Green Dot Corporation (NYSE: GDOT) is performing betterwhile Euronet Worldwide, Inc (NASDAQ: EEFT) has been a outperformer:

Merck, Cardinal Health Drop into Monday’s 52-Week Low Club

November 20, 2017: Here are four stocks trading with heavy volume among 64 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 3 to 2 and on the Nasdaq, advancers led decliners by about the same spread.

Merck & Co. Inc. (NYSE: MRK) dropped about 2.9% Monday to post a new 52-week low of $53.63 after closing at $55.02 on Friday. The 52-week high is $66.80. Volume was around 12.7 million, more than 25% above the daily average of about 10 million. The company’s chief competitor in a combo therapy for lung cancer reported a successful phase 3 trial.

Omega Healthcare Investors Inc. (NYSE: OHI) dropped about 2.6% Monday to post a new 52-week low of $26.43 after closing at $27.14 on Friday. The 52-week high is $35.14. Volume was around 5.3 million, more than double the daily average of around 2.3 million. The healthcare REIT had now specific news.

Curis Inc. (NASDAQ: CRIS) matched a 52-week low of $0.88 set Friday. The 52-week high is $3.48. Volume was about 4 million, four times the daily average of around 1 million. The drugmaker had no specific news Monday.

Cardinal Health Inc. (NYSE: CAH) dropped about 4.9% Monday to post a new 52-week low of $54.67 after closing at $57.51 on Friday. The stock’s 52-week high is $84.88. Volume of around 4 million was about 40% above the daily average. The drug distributor was named by Morgan Stanley as the most susceptible to an Amazon attack on the pharmaceuticals business.

24/7 Wall St.
Why This May Be the Perfect Time to Chase Warren Buffett’s Largest Stock Picks

10 stocks

My short thesis on Vera Bradley (VRA) is pretty simple. First, Vera Bradley’s business is declining:

Source: Author from VRA filings and press releases; EBITDA calculations mine, exclude one-time factors. FY18 numbers at midpoint of company guidance.

Second, I don’t think Vera Bradley’s management has any real answer to reverse those declines – and the continuing freefall in mall traffic could easily offset any assortment/marketing improvements, anyhow. And third, Vera Bradley still isn’t appropriately priced as a declining business. Multiples of 15x the midpoint of FY18 EPS guidance plus cash, and 5.3x EV/EBITDA might sound cheap. But they’re actually above most retail peers (particularly mall retailers), and both assume that earnings and/or cash flow stabilize in the not-too-distant future, and begin to grow again at some point.

10 stocks: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Jack Delaney]

    Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) have reportedly said it isn’t an “area of active research.” Bayer AG (OTCMKTS ADR: BAYRY), which bought a company that studied a male birth control pill in the 1990s, stopped research and development on male fertility control in 2006.

  • [By Mark Balson]

     Just as Jefferies diminished its price target on the stock to 53$ from 54$ and gave a “hold” rating, shares of Merck & Co. (MRK) started slithering by 0.44% to $56.00 on Wednesday morning.

    Kenilworth, NJ-based Merck is a global healthcare company, offering health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

  • [By Keith Speights]

    Investors have really liked Merck(NYSE:MRK) stock over the last 12 months, with shares jumping around 30%. Pfizer (NYSE:PFE) has performed pretty well also, but not nearly at the level of Merck. The big drugmaker’s stock is up close to 15%.

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage gain ahead of the close Friday was Merck & Co. Inc. (NYSE: MRK) which traded up 3.90% at $62.68. The stock’s 52-week range is $47.97 to $65.46. Volume was about 70% higher than the daily average of around 11.2 million shares. The company had no specific news Friday, but rival Bristol-Myers said this morning that it would not see accelerated approval for its lung cancer drug and that leaves Merck in the driver’s seat.

10 stocks: Net 1 UEPS Technologies, Inc.(UEPS)

Advisors’ Opinion:

  • [By Javier Hasse]

    Friday’s after-hours trading session did not see many stocks on the move. Shares of Net 1 UEPS Technologies Inc (NASDAQ: UEPS) were down almost 2.5 percent in what seemed like a correction of the 1.83 percent surge seen during the day.

10 stocks: Advanced Energy Industries, Inc.(AEIS)

Advisors’ Opinion:

  • [By Nelson Hem]

    While short sellers shied away from many of the leading solar stocks between the January 15 and January 29 settlement dates, two companies in particular led that trend. The number of Advanced Energy Industries, Inc. (NASDAQ: AEIS) and Sunedison Inc (NYSE: SUNE) shares sold short shrank by more than 10 percent by the end of the month.

10 stocks: Nuveen Select Tax Free Income Portfolio(NXP)

Advisors’ Opinion:

  • [By Eric Volkman]

    Income investors might be wary of Qualcomm, as the company loves to spend its money — at times, its dividend payouts and share buybacks have exceeded free cash flow. Compounding that matter, the company should soon close the door on its acquisition of European peer NXP Semiconductor (NYSE:NXP), a deal with an estimated enterprise value of $47 billion.